|
|
Post by barnstormer on Jun 24, 2021 9:16:11 GMT -5
Congratulations LA & VDEX on the new partnership with HealthClix. It just gives more credibility to the VDEX model. I see HealthClix will be offering spirometry testing soon to support Afrezza. I wonder if they support the Senseonics CGM to complement their remote monitoring of patients. What a combination that would be.
|
|
|
|
Post by barnstormer on May 13, 2021 9:23:53 GMT -5
That's what everyone thought about Afrezza. The stock would fly. Then reality set in and inhalable insulin didn't take off. Even Martine stated on an investor's call that there was no guarantee PAH patients would convert to Tyvaso. So I hope (not a good investment strategy) you're right and the stock triples. But that's what we hoped for with Afrezza. Hello Barnstormer, I read every word you have written and consider them. Consider the promise of COPD. COPD with Martine leading the charge. Perhaps that is what is being priced in. As far as partners, I am hoping CEO's look at what Martine is doing and wonder why she is having all the fun. Just talkin. Hi Peppy. Thanks for your input. I am not selling my shares yet, even though they go from red to green back to red based on my average and MNKDs volatility. I would love to see share price triple, but counting on Martine to save MNKD investors is a sad reflection on Mike and his bandits. Mike's inability to make Afrezza a success is a bad reflection on TS as a platform and hinders it IMHO from being considered by other formulations, thus the lack of other partners and growth. |
|
|
|
Post by barnstormer on May 13, 2021 8:32:49 GMT -5
That's what everyone thought about Afrezza. The stock would fly. Then reality set in and inhalable insulin didn't take off. Even Martine stated on an investor's call that there was no guarantee PAH patients would convert to Tyvaso. So I hope (not a good investment strategy) you're right and the stock triples. But that's what we hoped for with Afrezza.
|
|
|
|
Post by barnstormer on May 13, 2021 7:31:56 GMT -5
I haven't posted here for a while because as my mother used to say "If you can't say something nice, don't say anything" and so since I went from an enthusiastic investor in MNKD to a disillusioned cynic I have tried to follow that advice. This board has always been the best source of intelligent posts and knowledge and still is and with respect I will proceed. After yesterday's earnings call it has become impossible to be silent when it is quite apparent that my worst fears about the current CEO is well founded. Mike has been the artful dodger regarding the erosion of Afrezza scrips and it's time to cease his term as CEO. He was hired not to be a CEO, but to make Afrezza a success. What ever happened to the phrase "standard of care"? He collects a salary that is above his competence level and bonuses he doesn't deserve. You could hear the skepticism in the analysts voices as they asked their usual questions. Mike has talked about partners he has been negotiating with since he became CEO, but the only one we have is UTHR and he can't claim that one as his own. He has said he has been negotiating with Canada and Mexico for years with nothing to show. BIOM & CIPLA are disasters. He spent $12 million on a barn based (you can't make that up) Qrum company with no revenue, no FDA approved drugs and who knows how much more cash it will take to develop. He has been desperate to create the illusion of a pipeline (including RLS) that is years away from generating cash if they are successful. So IMHO it's time to end the Castagna experiment, time for Kresa to give up his seat on the BOD, for the ever expensive Tross to clear out his desk and bring in some fresh eyes or we will continue to be disappointed at all future earnings calls.
|
|
|
|
Post by barnstormer on Nov 6, 2020 14:21:10 GMT -5
Apparently now that Mike and teams option shares are vesting he is suddenly interested in avioding dillution. Hell, let's just sell the plant, we don;t want our shares dilluted. If he was truly creative and effective, this option wouldn't need to be considered. Al's life work is slowly being unravelled by amature CEOs Lol. Blows my mind why some people stay invested when they have similar opinions. This amateur ceo is going to make us a lot of money. Blows my mind that people have been saying that for years on this board and still believe their own BS. They can't point to anything specific, but they just keep hoping if they wait long enough, something good will happen. Rest & Grow = Rest & Hope. Neither is a sound investment strategy. But good luck to you. |
|
|
|
Post by barnstormer on Nov 6, 2020 7:51:40 GMT -5
Yes but the part about non dilutive financing is extra and sounds good . How much can the building be valued at? Enough to avoid a $30m round of dilution? The stock price loved the call. Shorts have been leaving. It’s time to back up the truck. The part I had emboldened seemed to me to be Mike saying the same thing about non dilutive financing. I suppose he said it in plainer language this time around. Apparently now that Mike and teams option shares are vesting he is suddenly interested in avioding dillution. Hell, let's just sell the plant, we don;t want our shares dilluted. If he was truly creative and effective, this option wouldn't need to be considered. Al's life work is slowly being unravelled by amature CEOs |
|
|
|
Post by barnstormer on Nov 5, 2020 9:29:06 GMT -5
Selling the plant shows that Afrezza revenue (oh yow the companies only real product) has no chance of reaching break even anytime soon. Most of the long term hope for ever seeing a recoup of share price now hinges on UTHR. If MC was any kind of CEO he would have been able to optimize the plant by finding other partners who needed manufacturing capacity. Look at all of the CV vaccine makers looking for capacity. As mentioned here before, MidCap has had to bless the transaction and it appears they would rather have MNKD sell it and pay back the loan than for them to foreclose and have to conduct a fire sale/auction. Any way you try to sugar coat this, it doesn't smell good.
|
|
|
|
Post by barnstormer on Nov 1, 2020 8:32:34 GMT -5
Wow! No posts of Mike in a Haloween costume this year? Starting to act like a real CEO? One could hope.
|
|
|
|
Post by barnstormer on Aug 2, 2020 9:14:29 GMT -5
I respect all of the comments/sentiments of the posts on this particular thread. I don't blame Covid for all of the problems because the uptick in scrips has lagged where it should be long before the pandemic. Sure it presented some headwind, but is not an excuse for the slippage. I have been around a number of CEOs and invested in companies because they have dynamic CEOs. A true CEO has to be a tireless promoter creating opportunities to get in front of every media outlet possible to expound on the virtues of their company and their product. Mike finishes as an "also ran" to take a term from horse racing. Many say he has made mistakes in marketing. I would agree. Example: the Indy sponsorship. I supported it because I attend the event regularly. The build up to the race is a media frenzy and coverage of drivers with diabetes has worked for Lilly. I contacted MNKD IR to see who from MNKD was attending. Response. No one. Mike will make a big deal out of attending an Eagles game, but didn't even attend an event he had spent big cash on. Indy sponsors are lavished with media coverage. Mike has attended many investors conference to showcase MNKD. His presentations are lack luster and his presentation skill are lame at best. The result? No partnerships, no investors. If there was ever an opportunity to find a loan with reasonable terms it would be at one of these conferences after a smoking presentation. Now he can't meet the terms of his latest "finacial re-engineering terms". Leaderhip personnel has become a revolving door of failures. I voted for him as CEO of the year in that stupid pole. I am voting him off the island now.
|
|
|
|
Post by barnstormer on Jul 22, 2020 23:59:06 GMT -5
If that were true I would expect Kendall to have seen the writing on the wall before joining. Surely someone of his stature knows how to do due diligence, plus he has the right connections to ask around. I didn’t spin anything, Kendall did very little during his time at MannKind—a handful of publications and some minor language changes in the SoC. Woooptyfuggindoo that does not justify what he was paid during his time at MannKind, IMO. And the truth is we just don't really know, nor will we ever. However, I can look at the qualifications and see that someone is just a bit outclassed. Mike bragged on many occasions about how he brought Kendall to Mannkind. What a great catch he was. Kendal pontificated about how Afrezza should be the new SOC and that other insulins were barbaric. As far as I can see as an underwater investor who was optimistic that those two would get MNKD on track to at least a double digit (setting the bar low) share price neither are worth the powder it would take to blow them up (euphemisim I'm nonviolent). All I see as hopeful now is that Galindo comes in as CCO and does to Mike just what he did to Matt P when Mike came in as CCO. It's time for a change at the top. I heard Mike presented at another investor conference a couple days ago. Is that true? No PR? I guess he wanted to spare himself from the embarrassment of disapointed shareholders clinging to hope he might actually put a deal together. |
|
|
|
Post by barnstormer on Jun 10, 2020 9:11:31 GMT -5
If only the insurance companys cared about patients quality of life.
|
|
|
|
Post by barnstormer on Jun 10, 2020 9:09:31 GMT -5
Abstract is here: diabetes.diabetesjournals.org/content/69/Supplement_1/990-PSummary: The study failed to achieve its primary endpoint of significant increase of time spent in glycemic goal range. Other benefits were seen as detailed further in the abstract. In other news: diabetes.diabetesjournals.org/content/69/Supplement_1/1023-PSummary: Dosing with Afrezza was compared to injectable prandial insulin and found that to achieve the same glycemic control it takes 1.3 to 2.5 times as many units of Afrezza to get the same result as injectable insulins. This is not news to anybody who follows MNKD, but it does have cost of therapy implications if an insurer is comparing the cost of administering 10 units of injectable to the cost of administering 20 units of Afrezza. "Patients treated with inhaled insulin with background basal insulin for 14 weeks experienced significant reduction of A1c and significant improvements of Useful, Freeing, and Difficult QoL subdomains compared to baseline". |
|
|
|
Post by barnstormer on May 25, 2020 10:27:20 GMT -5
Mannkind CEOs have made a number of presentations over the years touting and explaining the advantages of TS to safely infiltrate the enormous tissue base of the lungs to deliver insulin as well as other compounds. CV-19 is the latest, most publicized and tragic medical malady the world has seen. 100,000 lost souls so far in the US. Brazil recorded 15,000 new cases (not deaths thank god) in the last 24 hours. To date Mannkind has only garnered one CV-19 partner (Immix) who comes to the table with no credentials and no money to develop a product to aid in the effort to save lives. It was glossed over in the ASM and investors have no idea of what that relationship looks like and what they are really trying to accomplish. It is very troubling that this management team can't find any bonafide drug makers with cash other than UTHR to exploit the technology Al Mann spent a billion dollars of his own money to develop. Many investors are putting their hopes behind Hooper and Grancio to move MNKD out of the quagmire and move the company forward. That to me shows they have given up hope on their CEO. Many support Mike (as I once did) for keeping the lights on. I can't look over Mike's shoulder every day to see what he is doing to advance the value of TS and other intellectual property, but the results so far suck. But on a brighter note God bless all longs in this stock and have a safe and enjoyable Memorial Day.
|
|
|
|
Post by barnstormer on May 21, 2020 7:19:19 GMT -5
From MNKD IR The meeting portal allows shareholders to log in using their control number (provided by your broker). Once logged in, there is an input box on the portal webpage that allows shareholders to submit written questions. On our end, we will see a running list of questions that have been submitted. If they see the same questions asked they should be obligated to answer. A few I am submitting. Where are we with Canada and Mexico? What's the latest status on India trials? Why aren't we working on approval in UK? What is the opportunity for the CV 19 partnership & time line? When will we see revenue from Brazil? When do you expect to finsh peds trial and how will you market Afrezza to that patient group? To join the call: If you would like to attend the virtual meeting and you have your control number, please go to www.virtualshareholdermeeting.com/MNKD2020 15 minutes prior to the start of the meeting to log in. If you came through your brokerage firm's website and do not have your control number, you can gain access to the meeting by logging into your brokerage firm's website 15 minutes prior to the meeting start, selecting the shareholder communications mailbox to link through to the meeting and the control number will automatically populate |
|
|
|
Post by barnstormer on May 20, 2020 15:50:17 GMT -5
In the biopharma industry one cannot sacrifice time, resources and energy to "rest" One must always be moving forward, always innovating, always pushing the boundaries, always progressing "Rest and grow" is not a strategy—it's a death sentence Michael Castagna must go. Mango is right! There is no rest for the wicked. There is only "the quick and the dead". We are still looking for Mike's pulse. |
|
